作者：
Mainga,Hamaluba [1]
;
Samuel,Sang [1]
;
Benedict,Orindi [1]
;
Irene,Njau [1]
;
Henry,Karanja [1]
;
Naomi,Kamau [1]
;
John N,Gitonga [1]
;
Daisy,Mugo [1]
;
Daniel,Wright [2]
;
James,Nyagwange [1]
;
Bernadette,Kutima [1]
;
Donwilliams,Omuoyo [1]
;
Mwaganyuma,Mwatasa [1]
;
Caroline,Ngetsa [1]
;
Charles,Agoti [1]
;
Stanley,Cheruiyot [1]
;
Amek,Nyaguara [1]
;
Marianne,Munene [1]
;
Neema,Mturi [1]
;
Elizaphan,Oloo [1]
;
Lynette,Ochola-Oyier [1]
;
Noni,Mumba [1]
;
Cynthia,Mauncho [1]
;
Roselyne,Namayi [1]
;
Alun,Davies [1]
;
Benjamin,Tsofa [3]
;
Eunice W,Nduati [1]
;
Nadia,Aliyan [1]
;
Kadondi,Kasera [4]
;
Anthony,Etyang [4]
;
Amy,Boyd [1]
;
Adrian,Hill [5]
;
Sarah,Gilbert [5]
;
Alexander,Douglas [6]
;
Andrew,Pollard [5]
;
Philip,Bejon [2]
;
Teresa,Lambe [1]
;
George,Warimwe [3]
;
COV004 Vaccine Trial Group [2]
作者单位：
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
[1]
Oxford Vaccine Group, University of Oxford, Oxford, England, UK.
[2]
Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, England, UK.
[3]
Ministry of Health, Nairobi, Kenya.
[4]
The Jenner Institute, University of Oxford, Oxford, England, UK.
[5]
Pandemic Sciences Institute, University of Oxford, Oxford, England, UK.
[6]
DOI
10.12688/wellcomeopenres.19150.2
PMID
38707489
发布时间
2024-05-07
换一批
换一批
